Bikini vs Longitudinal Incision in Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
Launched by UNIVERSITY OF MIAMI · Feb 13, 2025
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different types of cuts (or incisions) made during a specific type of hip surgery called Direct Anterior Approach Total Hip Arthroplasty (THA). The goal is to find out if one type of incision leads to better healing of the wound and higher satisfaction for patients compared to the other type. If you are between the ages of 65 and 74, have a body mass index (BMI) of 30 or more, and are scheduled for a hip replacement surgery, you may be eligible to participate in this study.
Participants in this trial will receive one of the two incision types during their surgery and will be monitored for how well their wounds heal and how satisfied they feel with their surgery results. It's important to note that individuals with a lower BMI, those who have had previous surgery on the same hip, or those who cannot have spinal anesthesia will not be included. This study aims to improve surgical techniques and outcomes for future hip replacement patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with body mass index greater than or equal to 30
- • Patients undergoing primary unilateral DAA THA
- • Patients undergoing primary THA
- Exclusion Criteria:
- • Patients with body mass index less than 30
- • Patients with a history of prior open surgery on the affected hip
- • Patients unable/unwilling to undergo spinal anesthesia under monitored anesthesia care (MAC)
- • Patients with allergies or absolute contraindication to standardized drugs administered within the University of Miami protocol for total hip replacement
- • The following groups will not be included: adults unable to consent, individuals who are not yet adults, pregnant women, prisoners.
About University Of Miami
The University of Miami, a leading academic institution, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to explore new therapies and treatment modalities. Its extensive clinical programs are supported by state-of-the-art facilities and a diverse patient population, enabling the exploration of cutting-edge solutions to complex health challenges. The University of Miami is poised to contribute significantly to the field of medicine through its rigorous scientific inquiry and a steadfast commitment to ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Patients applied
Trial Officials
Victor H Hernandez, MD
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported